Near Infrared Analysis of Tablets Containing Two Active Ingredients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Near Infrared Analysis of Tablets Containing Two Active Ingredients
The study evaluates near-infrared analysis of tablets nominally containing 4 mg of chlorpheniramine maleate and 10 mg of phenylephrine hydrochloride per dose.


Pharmaceutical Technology
pp. 52-62

Experimental


Figure 3: Raw diffuse transmission spectra of calibration tablets.
Twelve batches of tablets that are 0.25 in. in diameter with a nominal weight of100 mg were formulated with a label claim of 10.0 mg phenylephrine hydrochloride (PE–HCl) and 4.0 mg chlorpheniramine maleate (CPM). The CPM and PE–HCl were varied by 20% of this label claim in a fractional factorial design of experiments (DOE). The lactose excipient was varied to maintain constant weight (see Table I). The tablets were compressed on a rotary tablet press (HT-AP 18 SS-U/I, Elizabeth Hata International) at the University of Tennessee's Pharmaceutical Sciences Department, the Memphis College of Pharmacy.


Figure 4: Second derivative math pretreatment of calibration spectra.
NIR method. The NIR instrument used in the study was an XDS MasterLab (FOSS NIRSystems). This instrument was used in the diffuse-transmission mode and sequentially measured multiple tablets positioned in a custom tray specifically designed for the tablets under test (see Figure 1). The tray was machined for 0.25-in. diameter tablets with +0.004-in. oversize tolerance for ease of fit and tablet placement without allowing stray light to pass around the tablet. Stray light is spectral energy that does not interact with the sample and therefore dilutes absorbance and reduces the sensitivity and linearity of the measurements. The MasterLab uses a standard indium–gallium–arsenide detector that has a dynamic range of more than 5.0 absorbance units. This absorbance range is required for measuring in the transmission mode through solid dosage forms. Maintaining low stray light is most important at these high absorbance levels (i.e., low light levels).


Figure 5: Predicted residual error sum of squares (PRESS) plot of partial least squares factors used to predict chlorpheniramine maleate concentration with seven factors.
The tray used for this study had 31 tablet positions and was loaded to scan 10 tablets from each batch. The 10 tablets were scanned in less than 3 min., taking a reference spectrum before scanning each batch. Spectra were collected from 800 nm to 1650 nm with 0.5-nm data intervals. Thirty-two spectral scans of each tablet were coadded to produce a single spectrum to enhance the signal-to-noise ratio.


Figure 6: Partial least squares loadings that indicate where chlorpheniramine maleate is highly correlated with spectral data. The structure of chlorpheniramine is superimposed.
HPLC method. HPLC analysis of the same tablets measured by NIR was performed at the University of Tennessee Pharmaceutical Sciences Department in the Memphis College of Pharmacy laboratory. The HPLC system was a Shimadzu vp series provided with an LC-10AD vp pump, an automatic injector SIL-10AD vp, an SPD-M10A vp diode array detector, and a DGU-14A degasser. The chromatographic analysis was performed on a 5-m particle Luna C18 column (150 4.6 mm) (Phenomenex) kept in a CTO-10A vp column oven (Shimadzu) at 35 C. Final chromatographic condition was an isocratic elution, and the mobile phase was methanol: acetonitrile: tri ethyl amine: 0.4 % sodium lauryl sulphate in the ratio of 350:300:1.5:350.


Figure 7: Calibration set. CPM is chlorpheniramine maleate, HPLC is high-performance liquid chromatography, and NIR is near infrared. R2 = 0.9811, Standard error of calibration = 0.0739 mg, Standard error of cross validation = 0.0901 mg.
The mobile phase pH was adjusted to 3.8 with o-phosphoric acid. The flow rate was 1 mL/min, and the injection volume was 20 l. Absorbance was measured at 215 nm, the wavelength of highest sensitivity for both phenylephrine and chlorpheniramine. Individual tablets were sonicated in methanol and with the mobile phase. The suspension was filtered using 0.22-m PTFE syringe filters. The samples were diluted with the mobile phase before being injected on to chromatography. The Shimadzu CLASS-VP software was used for analysis. Figure 2 is a representative chromatogram.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here